Effects of Survivin-T34A Mutant on Breast Cancer Cell <i>In Vitro</i> and <i>In Vivo</i>_Journal of Biomedical Engineering

Authors：

DENGXiaohui , SONGHaiyan ,  RENMingxin

Department of Human Anatomy, Xinxiang Medical University, Xinxiang 453003, China;

Corresponding author：

RENMingxin, Email: Hnlyrmx@163.com

Keywords：

Survivin-T34A; mutant; breast cancer; apoptosis

DOI：

10.7507/1001-5515.20140121

Video：

Export PDF Favorites Scan Get Citation

Abstract Full text Figures/Tables Video References Cited by

To study the effect of the proliferation and apoptosis of Survivin-T34A mutant on breast cancer MCF-7 cell, we adopted the method of cell culture in vitro to observe the proliferation and apoptosis of the cell. In the experiment, MCF-7 cells were randomly divided into three groups and transfected with normal saline, PORF-9-null and Survivin-T34A, respectively. Breast cancer nude mouse models were established to study anti-tumor effect of Survivin-T34A in vivo. The activity of the cells in the Survivin-T34A-transfected group was lower than that in PORF-9-null group. The increase of cell apoptosis was observed under electron microscopy, meanwhile the apoptotic rate was obviously higher than that in PORF-9-null control by flow cytometry. Tumor inhibition effects of the mouse which received the injection of Survivin-T34A intratumoral injection were apparent, and the inhibition ratio was as high as 47.1%. In conclusion, Survivin-T34A mutant has anti-tumor effect through efficiently inhibiting the growth of breast cancer MCF-7 cell and actively promoting apoptosis of cancer cells.

Citation： DENGXiaohui, SONGHaiyan, RENMingxin. Effects of Survivin-T34A Mutant on Breast Cancer Cell In Vitro and In Vivo. Journal of Biomedical Engineering, 2014, 31(3): 648-651. doi: 10.7507/1001-5515.20140121 Copy

1.	HUANG X, WONG M K, YI H, et al. Combined therapy of local and metastatic 4T1 breast tumor in mice using SU6668, an inhibitor of angiogenic receptor tyrosine kinases, and the immunostimulator B7.2-IgG fusion protein[J]. Cancer Res, 2002, 62(20):5727-5735.
2.	PENG X C, YANG L, YANG L P, et al. Efficient inhibition of murine breast cancer growth and metastasis by gene transferred mouse survivin Thr34→Ala mutant[J]. J Exp Clin Cancer Res, 2008, 27:46.
3.	LIAO C P, ADISETIYO H, LIANG M, et al. Cancer stem cells and microenvironment in prostate cancer progression[J]. Horm Cancer, 2010, 1(6):297-305.
4.	ZAHEDI P, AMINIMOGHADDAM S, SAYAHPOUR F A, et al. Association of survivin gene polymorphism with endometrial cancer[J]. Int J Gynecol Cancer, 2012, 22(1):35-37.
5.	TANIZAKI J, OKAMOTO I, FUMITA S, et al. Roles of BIM induction and survivin downregulation in lapatinib-induced apoptosis in breast cancer cells with HER2 amplification[J]. Oncogene, 2011, 30(39):4097-4106.
6.	潘黎,彭星辰,袁庆中,等.Survivin突变基因抗前列腺癌的体内外研究[J].四川大学学报(医学版),2010,41(3):390-393.
7.	YEH H W, GAJEWSKI B, MUKHOPADHYAY P, et al. The zero-truncated poisson with right censoring:an application to translational breast cancer research[J]. Stat Biopharm Res, 2012, 4(3):252-263.
8.	RYAN B M. O'DONOVAN N, DUFFY M J. Survivin:a new target for anti-cancer therapy[J]. Cancer Treat Rev, 2009, 35(7):553-562.
9.	GROSSMAN D, KIM P J, SCHECHNER J S, et al. Inhibition of melanoma tumor growth in vivo by survivin targeting[J]. Proc Natl Acad Sci U S A, 2001, 98(2):635-640.
10.	BADIE C, ITZHAKI J E, SULLIVAN M J, et al. Repression of CDK1 and other genes with CDE and CHR promoter elements during DNA damage-induced G(2)/M arrest in human cells[J]. Mol Cell Biol, 2000, 20(7):2358-2366.

1. HUANG X, WONG M K, YI H, et al. Combined therapy of local and metastatic 4T1 breast tumor in mice using SU6668, an inhibitor of angiogenic receptor tyrosine kinases, and the immunostimulator B7.2-IgG fusion protein[J]. Cancer Res, 2002, 62(20):5727-5735.
2. PENG X C, YANG L, YANG L P, et al. Efficient inhibition of murine breast cancer growth and metastasis by gene transferred mouse survivin Thr34→Ala mutant[J]. J Exp Clin Cancer Res, 2008, 27:46.
3. LIAO C P, ADISETIYO H, LIANG M, et al. Cancer stem cells and microenvironment in prostate cancer progression[J]. Horm Cancer, 2010, 1(6):297-305.
4. ZAHEDI P, AMINIMOGHADDAM S, SAYAHPOUR F A, et al. Association of survivin gene polymorphism with endometrial cancer[J]. Int J Gynecol Cancer, 2012, 22(1):35-37.
5. TANIZAKI J, OKAMOTO I, FUMITA S, et al. Roles of BIM induction and survivin downregulation in lapatinib-induced apoptosis in breast cancer cells with HER2 amplification[J]. Oncogene, 2011, 30(39):4097-4106.
6. 潘黎,彭星辰,袁庆中,等.Survivin突变基因抗前列腺癌的体内外研究[J].四川大学学报(医学版),2010,41(3):390-393.
7. YEH H W, GAJEWSKI B, MUKHOPADHYAY P, et al. The zero-truncated poisson with right censoring:an application to translational breast cancer research[J]. Stat Biopharm Res, 2012, 4(3):252-263.
8. RYAN B M. O'DONOVAN N, DUFFY M J. Survivin:a new target for anti-cancer therapy[J]. Cancer Treat Rev, 2009, 35(7):553-562.
9. GROSSMAN D, KIM P J, SCHECHNER J S, et al. Inhibition of melanoma tumor growth in vivo by survivin targeting[J]. Proc Natl Acad Sci U S A, 2001, 98(2):635-640.
10. BADIE C, ITZHAKI J E, SULLIVAN M J, et al. Repression of CDK1 and other genes with CDE and CHR promoter elements during DNA damage-induced G(2)/M arrest in human cells[J]. Mol Cell Biol, 2000, 20(7):2358-2366.

Journal of Biomedical Engineering

Effects of Survivin-T34A Mutant on Breast Cancer Cell In Vitro and In Vivo

Abstract Full text Figures/Tables Video References Cited by

Previous Article

Next Article

Format

Content